Document Detail


Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
MedLine Citation:
PMID:  18473965     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Placebo-controlled clinical trials have shown that atorvastatin is beneficial in patients with myocardial ischemia, established coronary artery disease, hypertension and 3 other cardiovascular risk factors (e.g. left-ventricular hypertrophy, type 2 diabetes, smoking), and in diabetes, but not in patients with calcific aortic stenosis. Recently, intensive low density lipoprotein (LDL)-cholesterol lowering with atorvastatin 80 mg/day has been shown to have a greater clinical benefit than atorvastatin 10 mg/day in patients with coronary heart disease and one other high-risk factor (previous myocardial infarction, coronary revascularization or angina), and to be superior to moderate lipid lowering with pravastatin (40 mg/day) in patients with an acute coronary syndrome. However, a smaller study comparing lovastatin 5 mg/day with atorvastatin 80 mg/day was unable to detect any difference in outcomes in patients with stable coronary disease, despite the greater LDL-cholesterol lowering with the atorvastatin, possibly because it was not powered to do so. In a retrospective cohort study, atorvastatin 10 mg/day, pravastatin 20 mg/day, simvastatin 20 mg/day, lovastatin 20 mg/day and fluvastatin 20 mg/day had similar efficacy as secondary prevention after acute myocardial infarction. At present, the evidence from clinical trials is favouring the intensity of the effect on LDL-cholesterol and/or C-reactive protein (CRP) with atorvastatin 80 mg, rather than the use of atorvastatin per se, when greater benefits are observed with the 80 mg dose of atorvastatin compared to other statins. Thus, at present, it is not clear whether atorvastatin is superior to other statins in some indications (coronary heart disease, acute coronary syndromes) or whether it is the intensive lipid lowering that is responsible for the superiority. Atorvastatin has little or no ability to increase high density lipoprotein (HDL)-cholesterol, and this may be a disadvantage in patients with metabolic syndrome or diabetes, where low HDL-cholesterol is a key feature. Thus, other statins should probably be preferred to atorvastatin in patients with diabetes/metabolic syndrome. Alternatively, atorvastatin can be used in combination with a fibrate to increase HDL-cholesterol in patients with diabetes/metabolic syndrome.
Authors:
Sheila A Doggrell
Related Documents :
17652885 - Randomized trial of statin administration for myocardial injury: is intensive lipid-low...
4020295 - Studies of low density lipoprotein molecular weight in human beings with coronary arter...
3295315 - Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis an...
10695705 - Strategies for implementing lipid-lowering therapy: pharmacy-based approach.
22536125 - Visualization of chronic myocardial infarction using the intravascular contrast agent m...
24500905 - Vitamin d receptor genetics on extracellular matrix biomarkers and hemodynamics in syst...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Reviews on recent clinical trials     Volume:  1     ISSN:  1574-8871     ISO Abbreviation:  -     Publication Date:  2006 May 
Date Detail:
Created Date:  2008-05-13     Completed Date:  2008-06-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270873     Medline TA:  Rev Recent Clin Trials     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  143-53     Citation Subset:  IM    
Affiliation:
Division of Health Practice, Auckland University of Technology, Northcote, Auckland, New Zealand. s_doggrell@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / therapeutic use
Anticholesteremic Agents / therapeutic use*
Azetidines / therapeutic use
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic*
Clofibric Acid / therapeutic use
Fatty Acids, Monounsaturated / therapeutic use
Fluorobenzenes / therapeutic use
Heptanoic Acids / therapeutic use*
Humans
Indoles / therapeutic use
Pravastatin / therapeutic use
Pyrimidines / therapeutic use
Pyrroles / therapeutic use*
Simvastatin / therapeutic use
Sulfonamides / therapeutic use
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Azetidines; 0/Fatty Acids, Monounsaturated; 0/Fluorobenzenes; 0/Heptanoic Acids; 0/Indoles; 0/Pyrimidines; 0/Pyrroles; 0/Sulfonamides; 110862-48-1/atorvastatin; 163222-33-1/ezetimibe; 287714-41-4/rosuvastatin; 79902-63-9/Simvastatin; 81093-37-0/Pravastatin; 88150-42-9/Amlodipine; 882-09-7/Clofibric Acid; 93957-54-1/fluvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Iodine-refractory thyroid carcinoma.
Next Document:  Towards a gene therapy clinical trial for epidermolysis bullosa.